Holding pharmaceutical companies to account
Our legal, medical, and policy experts collect examples where pharmaceutical companies are suspected of using their monopolies to charge excessive prices for medicines. We investigate these and, if evidence of malfeasance is found, may bring a case.
Other Cases of Interest:
- mexiletine (Namuscla, message in Dutch only)
- pyrimethamine (Daraprim)
- lithium (Priadel)
We investigate practices around the accessibility and availability of medicines, and call pharmaceutical companies to account if these are unacceptable. If necessary, we take legal action. But we cannot do this alone – please support us!
By signing our endorsement letter, you show that our work is supported by many people, this may have added value in a legal action. You can also donate or join as a volunteer. We would love to hear how you want to get involved: please contact us.